Sensei Biotherapeutics, Inc. – NASDAQ:SNSE
Sensei Biotherapeutics stock price today
$7.9
+7.40
+1486.35%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Sensei Biotherapeutics stock price monthly change
-31.30%
month
Sensei Biotherapeutics stock price quarterly change
-31.30%
quarter
Sensei Biotherapeutics stock price yearly change
-28.43%
year
Sensei Biotherapeutics key metrics
Market Cap | 11.50M |
Enterprise value | 35.06M |
P/E | -0.93 |
EV/Sales | N/A |
EV/EBITDA | -0.50 |
Price/Sales | N/A |
Price/Book | 0.43 |
PEG ratio | 0.02 |
EPS | -1.21 |
Revenue | N/A |
EBITDA | -33.16M |
Income | -31.91M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSensei Biotherapeutics stock price history
Sensei Biotherapeutics stock forecast
Sensei Biotherapeutics financial statements
| Jun 2023 | 0 | -9.38M | |
|---|---|---|---|
| Sep 2023 | 0 | -7.12M | |
| Dec 2023 | 2.84M | -7.41M | -260.51% |
| Mar 2024 | 0 | -7.99M |
| 2025 | 0 | -41.28M | |
|---|---|---|---|
| 2026 | 0 | -48.29M | |
| 2027 | 0 | -38.57M | |
| 2028 | 0 | -38.57M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 89580000 | 10.37M | 11.59% |
|---|---|---|---|
| Sep 2023 | 81658000 | 10.65M | 13.05% |
| Dec 2023 | 74374000 | 9.47M | 12.75% |
| Mar 2024 | 66694999 | 8.22M | 12.33% |
| Jun 2023 | -9.46M | 19.52M | -7.94M |
|---|---|---|---|
| Sep 2023 | -4.66M | 8.31M | -2.53M |
| Dec 2023 | -6.16M | 8.26M | -431K |
| Mar 2024 | -7.61M | 5.77M | -209K |
Sensei Biotherapeutics alternative data
| Aug 2023 | 27 |
|---|---|
| Sep 2023 | 23 |
| Oct 2023 | 23 |
| Nov 2023 | 23 |
| Dec 2023 | 26 |
| Jan 2024 | 26 |
| Feb 2024 | 26 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 27 |
Sensei Biotherapeutics other data
1.08%
-7.52%
of SNSE is owned by hedge funds
13
-14
330.31K
-2.31M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 2200 | 0 |
| Jun 2023 | 0 | 955738 |
| Sep 2023 | 500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CELEBI JOHN director, officer.. | Common Stock | 500 | $0.85 | $425 | ||
Sale | APEIRON INVESTMENT GROUP LTD. 10 percent owner | Common Stock | 955,738 | $1.58 | $1,510,066 | ||
Purchase | APEIRON INVESTMENT GROUP LTD. 10 percent owner | Common Stock | 1,100 | $1.6 | $1,762 | ||
Purchase | APEIRON INVESTMENT GROUP LTD. 10 percent owner | Common Stock | 1,100 | $1.62 | $1,777 | ||
Purchase | CAMBRIAN BIOPHARMA INC 10 percent owner | Common Stock | 1,203 | $3.2 | $3,850 | ||
Purchase | PEYER JAMES director, 10 percent owner | Common Stock | 1,203 | $3.2 | $3,850 | ||
Purchase | CAMBRIAN BIOPHARMA INC 10 percent owner | Common Stock | 2,458 | $3.6 | $8,849 | ||
Purchase | PEYER JAMES director, 10 percent owner | Common Stock | 2,458 | $3.6 | $8,849 | ||
Purchase | CAMBRIAN BIOPHARMA INC 10 percent owner | Common Stock | 42 | $3.6 | $151 | ||
Purchase | PEYER JAMES director, 10 percent owner | Common Stock | 42 | $3.6 | $151 |
| Patent |
|---|
Application Filling date: 1 May 2020 Issue date: 5 Nov 2020 |
Application Filling date: 18 Oct 2019 Issue date: 23 Apr 2020 |
Application Filling date: 10 May 2019 Issue date: 14 Nov 2019 |
-
What's the price of Sensei Biotherapeutics stock today?
One share of Sensei Biotherapeutics stock can currently be purchased for approximately $7.9.
-
When is Sensei Biotherapeutics's next earnings date?
Unfortunately, Sensei Biotherapeutics's (SNSE) next earnings date is currently unknown.
-
Does Sensei Biotherapeutics pay dividends?
No, Sensei Biotherapeutics does not pay dividends.
-
How much money does Sensei Biotherapeutics make?
Sensei Biotherapeutics has a market capitalization of 11.50M.
-
What is Sensei Biotherapeutics's stock symbol?
Sensei Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SNSE".
-
What is Sensei Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sensei Biotherapeutics?
Shares of Sensei Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sensei Biotherapeutics's key executives?
Sensei Biotherapeutics's management team includes the following people:
- Mr. John K. Celebi Pres, Chief Executive Officer & Director(age: 53, pay: $532,630)
- Dr. Robert Hamilton Pierce M.D. Chief Scientific Officer(age: 61, pay: $488,030)
-
How many employees does Sensei Biotherapeutics have?
As Jul 2024, Sensei Biotherapeutics employs 27 workers, which is 4% less then previous month and 4% less then previous quarter.
-
When Sensei Biotherapeutics went public?
Sensei Biotherapeutics, Inc. is publicly traded company for more then 4 years since IPO on 4 Feb 2021.
-
What is Sensei Biotherapeutics's official website?
The official website for Sensei Biotherapeutics is senseibio.com.
-
Where are Sensei Biotherapeutics's headquarters?
Sensei Biotherapeutics is headquartered at 451 D Street, Rockville, MD.
-
How can i contact Sensei Biotherapeutics?
Sensei Biotherapeutics's mailing address is 451 D Street, Rockville, MD and company can be reached via phone at +240 2438000.
Sensei Biotherapeutics company profile:
Sensei Biotherapeutics, Inc.
senseibio.comExchange:
NASDAQ
Full time employees:
28
Industry:
Biotechnology
Sector:
Healthcare
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
451 D Street
Rockville, MD 02210
Rockville, MD 02210
CIK: 0001829802
ISIN: US81728A1088
CUSIP: 81728A108
